Note: Where available, the PDF/Word icon below is provided to view the complete and fully formatted document
 Download Current HansardDownload Current Hansard    View Or Save XMLView/Save XML

Previous Fragment    Next Fragment
Thursday, 20 June 2013
Page: 6500

Mr NEUMANN (BlairParliamentary Secretary for Health and Ageing and Parliamentary Secretary to the Attorney-General) (13:15): I seek leave to make an amendment to this private members' motion.

Leave granted.

Mr NEUMANN: I move:

That the motion be amended to read—

"That this House:

(1) notes the concerns of key stakeholders in relation to the price reduction of chemotherapy drug Docetaxel and its potential broader impact on the treatment of cancer patients;

(2) notes that the Government:

(a) has announced a review into arrangements for funding chemotherapy services;

(b) is providing $29.7 million in the 2013-14 Budget to pay providers an additional $60 for each chemotherapy infusion on an interim basis for six months, to cover the review period between 1 July 2013 and 31 December 2013, in addition to current fees of $76.37; and

(c) demonstrated it was committed to providing drugs for cancer patients, having added 30 new drugs to treat 15 different cancers at an additional cost of $1.3 billion to the Pharmaceutical Benefits Scheme since 2007; and

(3) welcomes the policy of Accelerated and Expanded Price Disclosure of items on the Pharmaceutical Benefits Scheme"

Mr Pyne: Madam Deputy Speaker, I bring your attention to the state of the House.

(Quorum formed)

The DEPUTY SPEAKER ( Ms Hall ): The immediate question is that the amendment be agreed to.

A division having been called and the bells having been rung—

The SPEAKER: The division has been called off with the agreement of the Leader of the House and the Manager of Opposition Business. The Leader of the House has the call.